Try our Advanced Search for more refined results

BAXTER HEALTHCARE CORPORATION et al v. HQ SPECIALTY PHARMA CORPORATION

  1. July 05, 2017

    HQ's Heart-Drug Generic Would Flout Baxter Deal, Judge Says

    A New Jersey federal judge has blocked HQ Specialty Pharma Corp. from seeking the U.S. Food and Drug Administration's approval for a new generic version of Baxter Healthcare Corp.'s antiarrhythmic drug Brevibloc, ruling the action would violate an earlier settlement resolving patent infringement allegations.

  2. February 23, 2016

    HQ Settles Baxter's Dispute Over Arrhythmia Drug Generic

    HQ Specialty Pharma Corp. resolved Baxter Healthcare Corp.'s suit over a generic version of the antiarrhythmic drug Brevibloc, after a New Jersey federal judge allowed allegations that HQ misappropriated trade secrets, according to a Monday court filing.

  3. January 27, 2016

    Baxter Keeps Trade Secret Claims In HQ Arrhythmia Drug Suit

    A New Jersey judge has allowed Baxter Healthcare Corp. to pursue allegations that HQ Specialty Pharma Corp. misappropriated trade secrets in developing a generic version of anti-arrhythmia drug Brevibloc, maintaining certain state law and inventorship claims based on a former Baxter scientist's involvement in the allegedly infringing product.

  4. September 24, 2015

    Generics Maker Can't Duck Baxter Suit Over Brevibloc

    Generics maker HQ Specialty Pharma Corp. must face Baxter Healthcare Corp.'s infringement suit over the generic version of the anti-arrhythmia drug Brevibloc after a New Jersey federal judge refused to toss a patent dispute Wednesday, saying both parties' motions for summary judgment rested on disputed issues of fact.